Boehringer Ingelheim Pharmaceuticals Inc. et al v. InvaGen Pharmaceuticals, Inc.
| Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharmaceuticals Inc. and Boehringer Ingelheim International GmbH |
| InvaGen Pharmaceuticals, Inc. |
| 1:2018cv01788 |
| November 13, 2018 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on January 11, 2019. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 12 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Cipla Limited for InvaGen Pharmaceuticals, Inc. filed by InvaGen Pharmaceuticals, Inc.. (Phillips, John) |
| Filing 11 ANSWER to #1 Complaint, Affirmative Defenses, COUNTERCLAIM against All Plaintiffs by InvaGen Pharmaceuticals, Inc..(Phillips, John) |
Filing 10
Order Setting Scheduling Conference: A Scheduling Conference is set for 3/4/2019 at 02:30 PM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 1/3/2019. Associated Cases: 1:18-cv-01689-CFC et al.(nmf)
|
| Filing 9 Letter to The Honorable Colm F. Connolly from Jack B. Blumenfeld regarding coordinated discovery and Markman proceedings, and to request a scheduling conference. (Blumenfeld, Jack) |
|
Filing 8
ORDER, IT IS ORDERED that, on or before January 2, 2019, counsel for plaintiffs shall inform the court as to whether the need for coordinated discovery and/or Markman proceedings is anticipated as to the above cases and, if so, when a joint scheduling conference might most efficiently be conducted. ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 1/2/2019.) Signed by Judge Colm F. Connolly on 12/17/2018. Associated Cases: 1:18-cv-01689-CFC et al.(nmf)
|
|
SO ORDERED, re #7 STIPULATION TO EXTEND TIME to Answer or otherwise respond to the Complaint to January 11, 2019 filed by InvaGen Pharmaceuticals, Inc., Set/Reset Answer Deadlines: InvaGen Pharmaceuticals, Inc. answer due 1/11/2019. Signed by Judge Colm F. Connolly on 12/11/2018. (fms)
|
| Filing 7 STIPULATION TO EXTEND TIME to Answer or otherwise respond to the Complaint to January 11, 2019 - filed by InvaGen Pharmaceuticals, Inc.. (Phillips, John) |
| Filing 6 DECLARATION of Mailing on InvaGen Pharmaceuticals, Inc. by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc.. (Blumenfeld, Jack) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:18-cv-01757-CFC, 1:18-cv-01758-CFC, 1:18-cv-01762-CFC through 1:18-cv-01765-CFC, 1:18-cv-01779-CFC, 1:18-cv-01783-CFC, and 1:18-cv-01785-CFC through 1:18-cv-01789-CFC (rjb) |
| Summons Issued with Magistrate Consent Notice attached as to InvaGen Pharmaceuticals, Inc. on 11/14/2018. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (nmg) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc.. (nmg) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,949,998 B2. (nmg) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/2/2018. Date of Expiration of Patent: 6/11/2034.Thirty Month Stay Deadline: 2/1/2022. (nmg) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Filing 1 COMPLAINT for PATENT INFRINGEMENT filed against InvaGen Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2502848.) - filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation. (Attachments: #1 Exhibit 1, #2 Civil Cover Sheet)(nmg) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
